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IL-21 Enhances Antitumor Responses without
Stimulating Proliferation of Malignant T Cells
of Patients with Se´zary Syndrome
Jessica S. Yoon1, Sarah M. Newton1, Maria Wysocka1, Andrea B. Troxel2, Stephen D. Hess1, Stephen K.
Richardson1, Julie H. Lin1, Bernice M. Benoit1, Monika Kasprzycka3, Mariusz A. Wasik3 and Alain H. Rook1
IL-21, a common g-chain cytokine secreted by activated CD4þ T cells, influences both humoral and cell-
mediated immune responses through the regulation of T, B, dendritic, and natural killer (NK) cells. Se´zary
syndrome is an advanced form of cutaneous T-cell lymphoma, a clonally derived malignancy of CD4þ T cells
that is characterized by profound defects in host cellular immune function. As a modulator of both innate and
adaptive immune responses, IL-21 could play an important role in augmenting cell-mediated immunity in these
patients. Normal donor and Se´zary syndrome patient peripheral blood mononuclear cells were cultured with
IL-21 and tested for CD8þ T- and NK-cell activation, NK-cell cytotoxicity, and tumor cell proliferation and
apoptosis. IL-21 resulted in a modest increase in CD8þ T- and NK-cell activation, associated with a marked
increase in cytolytic activity against both K562 and malignant CD4þ T-cell targets. Although IL-21 failed to
demonstrate pro-apoptotic effects on the malignant CD4þ T cells, it is noteworthy that it had no demonstrable
proliferative effects on these cells. Thus, IL-21 may play an important role in enhancing the host immune
response of Se´zary syndrome patients through the increased cytolytic activity of T and NK cells.
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INTRODUCTION
Cutaneous T-cell lymphoma is a clonally derived malignant
proliferation of skin-invasive T cells. Se´zary syndrome is an
advanced form of the disease, characterized by profound
defects in host cellular immune function, including a
depressed Th1 response and a decreased number of dendritic
cells, CD8þ T cells, and CD56þ natural killer (NK) cells
(Rook and Heald, 1995; Diamandidou et al., 1996; Yoo et al.,
2001; Wysocka et al., 2002; Kupper and Fuhlbrigge, 2004).
Biologic response modifiers targeted at enhancing cell-
mediated immunity have become increasingly prevalent as
cancer therapeutic agents and are used with some success in
the treatment of Se´zary syndrome. A number of therapies, such as
IFNa and bexarotene, are currently in clinical use, and several
others, such as the CPG oligodeoxynucleotides, IFNg, IL-12,
IL-15, and IL-18, are in various stages of clinical and preclinical
development (Kaplan et al., 1990; Rook et al., 1999a,b; Wysocka
et al., 2004; McGinnis et al., 2005). Many biologics in clinical
use, however, produce significant adverse effects at the dosage
required for adequate potency, thus limiting their efficacy and
necessitating the continued search for new therapeutic agents
(Rook et al., 1998; Suchin et al., 2002; Vittorio et al., 2002).
IL-21, the most recently discovered member of the
common g-chain cytokine family, which includes IL-2, IL-4,
IL-7, IL-9, IL-15, and IL-21, is secreted by activated CD4þ
T cells (Leonard and Spolski, 2005). It has been found to have
pleotropic effects on immune function, influencing both
humoral and cell-mediated immune responses through the
regulation of T, B, dendritic, and NK cells (Parrish-Novak
et al., 2000, 2002). IL-21 has been shown to increase the
cytotoxicity of both NK (Kasaian et al., 2002) and CD8þ
T cells (Zeng et al., 2005) and to have potent antitumor
activity in several animal models, including metastatic
lymphoma, without observed toxic side effects (Kishida
et al., 2003; Ma et al., 2003; Ugai et al., 2003a, b; Wang
et al., 2003; Brady et al., 2004; DiCarlo et al., 2004; Moroz
et al., 2004; Zeng et al., 2005). Importantly, in contrast to
other common g-chain cytokines being studied for potential
antitumor activity, such as IL-2, IL-21 has been shown to
induce long-term survival in mice even when administered at
advanced stages of disease (Moroz et al., 2004).
In this study, we demonstrate that IL-21 activates CD8þ
T cells and NK cells and increases cytolytic activity of cells
derived from Se´zary syndrome patients, without causing
tumor cell proliferation or apoptosis. Given the reported
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marked antitumor effects and low toxicity combined with our
findings of this study showing a significant increase in NK-
cell cytotoxicity, we hypothesize that IL-21 might induce
antitumor responses in the treatment of Se´zary syndrome.
RESULTS
IL-21 upregulates CD69 expression on CD8þ T and NK cells
derived from Se´zary syndrome patients’ peripheral blood
To study the effect of IL-21 on CD8þ T- and NK-cell
activation, we studied the expression of CD69, which is
generally present only after activation (Sun et al., 1998;
Kranzer et al., 2000). Peripheral blood mononuclear cells
(PBMCs) from six healthy donors and six Se´zary syndrome
patients were incubated in IL-21 (25 ng/ml) for 36 hours.
A modest but statistically significant increase in CD69
expression on CD56/16þ NK cells and CD8þ T cells from
both normal donors’ and Se´zary syndrome patients’ cells was
observed (Figure 1a and b). For CD8þ T cells, CD69
expression on cells from Se´zary patients was not only equal
to that of normal donors’ cells following culture with IL-21,
but also the magnitude of the increase was significantly
higher for patients’ cells (Figure 1c). For CD56þ /CD16þ
NK cells, the increase in CD69 expression for IL-21-treated
cells from Se´zary syndrome patients when compared to
medium was equal to the increase for normal donors’ cells
(Figure 1d), although the overall expression of CD69 was
lower for patients’ cells. Although the overall upregulation of
CD69 expression for IL-21-treated CD8þ T and CD56/16þ
NK cells is small, these data suggest that patients’ CD8þ
T and CD56/16þ NK cells have not lost the ability to respond
to IL-21, and that this responsiveness may even be enhanced
for CD8þ T cells when compared to normal donors’ cells.
IFNc production by PBMCs from Se´zary syndrome patients
is variable in response to IL-21
Previous studies have reported that IL-21 can induce IFNg
production by both CD8þ T cells and NK cells (Kasaian
et al., 2002; Ma et al., 2003; Brady et al., 2004; Alves et al.,
2005). As IFNg is a potent immune modulatory agent in the
treatment of a variety of cancers (Street et al., 2001),
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Figure 1. CD69 expression on CD8þ T cells and NK cells in normal donors’ and patients’ PBMCs cultured in medium alone and with IL-21. PBMCs
from six Se´zary syndrome patients and six normal donors were cultured in medium alone or with IL-21 (25 ng/ml) for 36 hours. Cells were then harvested,
stained with the appropriate antibodies, and analyzed for the expression of CD69 on CD56þ /CD16þ NK cells and CD8þ T cells by flow cytometry.
Data represents means (þ SD) of tested individuals. (a) The average (Avg) percent of CD8þ T cells expressing CD69 was significantly greater for IL-21-treated
cells than for cells cultured in medium for normal (Nml) donors’ cells (Po0.05) and patients’ cells (Pt) (Po0.004). (b) The average (Avg) percent of
CD56þ /16þ NK cells expressing CD69 was significantly greater for IL-21-treated cells than for cells cultured in medium for normal donors’ cells (Nml)
(Po0.01) and patients’ cells (Pt) (Po0.004). (c) The average (Avg) percent increase over medium in CD69 expression on CD8þ T cells treated with IL-21 was
significantly greater for patients’ cells (Pt) than for normal donors’ cells (Nml) (Po0.004). (d) the average (Avg) percent increase over medium in CD69
expression on CD56/16þ NK cells treated with IL-21 was not significantly different in patients’ cells (Pt) compared with normal donors’ cells (Nml). Data
represent means (þ SD) of tested individuals.
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including Se´zary syndrome (McGinnis et al., 2005), we
investigated the effect that IL-21 has on the production of this
cytokine by PBMCs in vitro. PBMCs from 11 Se´zary
syndrome patients and 5 normal donors were treated with
IL-21 at 25 ng/ml for 72 hours. Supernatants were then
collected and analyzed by ELISA for IFNg. IFNg levels in
the supernatant fluid were elevated in samples from 9 of the
11 patients (Figure 2a); however, the degree of increase was
variable (Figure 2b). In contrast, none of the five normal
donors tested showed any increase in IFNg levels after
treatment with IL-21 (data not shown).
IL-21 stimulation of PBMCs from Se´zary syndrome patients
results in a significant increase in NK-cell cytotoxicity using
K562 erythroleukemia cells as targets
In a variety of animal models, increased activation of NK
cells has been found to be associated with enhanced end-
effector function after exposure to IL-21, resulting in greatly
enhanced cytotoxicity (Kasaian et al., 2002). To test the
cytolytic activity of NK cells, PBMCs from eight normal
donors and eight patients—four light tumor burden and four
heavy tumor burden—were incubated in medium alone or
with IL-21 (25 ng/ml) for 36 hours and a cytotoxicity assay
was performed, as described above. For normal, light tumor
burden and heavy tumor burden patients’ cells, treatment
with IL-21 resulted in a significant increase in the cytolytic
response compared to cells cultured in medium alone (Figure
3a). Furthermore, although the percent of specific lysis of
targets killed in the patient groups was lower than in the
normal group, the magnitude of the response of both light
and heavy tumor burden patients’ cells treated with IL-21 was
even greater than that of normal donors’ cells (Figure 3b).
IL-21 stimulation of PBMCs from Se´zary syndrome patients
results in a significant increase in NK-cell cytotoxicity against
Se´zary cells
It is important to establish that Se´zary patients’ NK cells are
capable of directing this increased cytotoxic response not
only against an established NK target cell line but also toward
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Figure 2. IFNc levels in supernatants collected from normal donors’ and
patients’ PBMCs cultured in medium alone and with IL-21. PBMCs from 11
Se´zary syndrome patients were cultured in medium alone or with IL-21
(25 ng/ml) for 72 hours. Cytokine levels were measured in cell-free
supernatants by ELISA. (a) IFNg levels (pg/ml) in supernatants collected from
11 patients’ cells (Pt). (b) The percent increase in IFNg levels in supernatants
from IL-21-treated patients’ cells over medium (Pt).
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Figure 3. Cell lysis for normal donors’ and patients’ PBMCs treated in
medium alone or with IL-21. PBMCs from four normal donors, four light
tumor burden patients, and four heavy tumor burden patients were cultured in
medium alone or with IL-21 (25 ng/ml), followed by a 4 hour Cr51-release
assay using K562 as targets. A subsequent assay was performed using PBMCs
from four additional Se´zary syndrome patients using cells from the SZ-4
Se´zary cell line as targets. (a) There is a significant increase in average (Avg)
K562 target lysis in IL-21-treated groups in normal donors’ cells (Po0.01),
light tumor burden patients’ cells (Po0.04), and heavy tumor burden patients’
cells (Po0.02) compared to cells cultured in medium alone. (b) IL-21-treated
cells show significantly greater percent increase in cell lysis when compared
to cells cultured in medium alone for light tumor burden patients’ cells
compared to normal donors’ cells (Po0.007) and for heavy tumor burden
patients’ cells compared to normal donors’ cells (Po0.03). (c) There is a
significant increase in SZ-4 target cell lysis in IL-21-treated Se´zary syndrome
patients’ cells (Pt) (Po0.02) compared to cells cultured in medium. Data
represent means (þ SD) of tested individuals.
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malignant Se´zary tumor cells. To test the patients’ response to
Se´zary cells, cytotoxicity assays were performed using
PBMCs from four normal donors and four Se´zary syndrome
patients using target cells from a well-established cell line
(SZ-4) originally isolated from a Se´zary patient. Patients’ cells
incubated in IL-21 showed a significant increase in the
cytolytic response to SZ-4 cells when compared to medium
(Figure 3c). In contrast, normal donors’ cells did not show a
statistically significant difference in SZ-4 lysis after culture
with IL-21 (data not shown). This suggests that the patients’
NK-cell responses against Se´zary cells may be enhanced
compared to normal donors.
IL-21 receptor mRNA may be upregulated in Se´zary syndrome
patients’ cells
To identify factors that may contribute to the enhanced
cytotoxicity of patients’ cells, both IL-21 receptor (IL-21R)
and IL-21 mRNA levels were tested in patients’ and normal
donors’ PBMCs by real-time PCR. PBMCs stimulated for
16 hours with plate-bound anti-CD3 in the presence of
soluble anti-CD28 were used as a positive control. Our
results show that IL-21R mRNA levels may be greater in
patients’ cells than in normal donors’ cells, although the
difference approached but did not reach statistical signifi-
cance (Figure 4). In contrast, IL-21 mRNA levels were
negligible in both groups and did not differ in normal donors’
cells when compared to patients’ cells (data not shown).
IL-21 does not induce proliferation of CD4þ /CD26 tumor
cells
IL-21 alone has not been shown to cause proliferation of
T cells (Parrish-Novak et al., 2000), although it has been found
to enhance T-cell proliferation when combined with certain
other cytokines, including IL-2, IL-7, and IL-15 (Parrish-
Novak et al., 2000; Kasaian et al., 2002). To test the
proliferative effects of IL-21 on tumor cells, PBMCs from three
patients with heavy tumor burdens and from three normal
donors were labeled with carboxyfluorescein diacetate
succinimidyl ester and cultured for 4 days with medium
alone or plate-bound anti-CD3 antibody (0.5 mg/ml) in the
presence of soluble anti-CD28 antibody (0.5 mg/ml) and then
stained with anti-CD26 and anti-CD4 antibodies. As des-
cribed previously, tumor cells were defined as CD26
CD4þ cells. All cell populations were evaluated, including
all lymphocytes, CD4þ T cells, and CD4þ /CD26 T cells
in both normal donors and patients. IL-21 failed to induce
proliferation in any cell population. This is in contrast to
stimulation with plate-bound anti-CD3 in the presence of
anti-CD28, which induced proliferation in all the normal
donors and Se´zary syndrome patient lymphocyte cell
populations tested (Po0.05; Figure 5a and b).
IL-21 does not cause apoptosis of CD4þ /CD26 tumor cells
As IL-21 has been found to have potent antitumor activity in a
number of mouse models and has been shown to induce
apoptosis of both B and NK cells (Kasaian et al., 2002; Mehta
et al., 2003; Wang et al., 2003; Brady et al., 2004; Jin et al.,
2004; Ozaki et al., 2004), we tested the ability of IL-21 to
induce apoptosis of malignant T cells. PBMCs were isolated
from heavy tumor burden patients, cultured with IL-21 (25 ng/
ml) or camptothecin as a positive control for 48, 72, and
96 hours, and a TUNEL assay was performed as described
previously. Results from all time points indicate that IL-21
does not have pro-apoptotic effects on the malignant cells
(Figure 6), which is in agreement with animal studies also
reporting that IL-21 lacks the ability to cause tumor cell
apoptosis (Wang et al., 2003).
DISCUSSION
Se´zary syndrome patients have defects in both innate and
adaptive immune responses, resulting in an impaired ability
to eliminate malignant cells. It is, therefore, critical that new
therapies are developed that can increase the responsiveness
of both components of the immune system. IL-21 could be
one such agent, as it is thought to be a ‘‘bridge’’ between the
innate and adaptive immune responses by causing an
immediate rise in NK cytolytic activity followed by a
sustained increase in antigen-specific CD8þ T-cell activity
(Parrish-Novak et al., 2000; Kasaian et al., 2002; Ma et al.,
2003; Wang et al., 2003; Moroz et al., 2004).
Our results show that in vitro culture with IL-21
significantly enhances Se´zary syndrome patients’ NK cytoly-
tic activity and results in a modest level of activation.
Importantly, this enhanced cytolysis is seen not only against
K562 erythroleukemia target cells, but also toward SZ-4 cell
line targets, a cell line originally established using a
malignant clone from a patient with Se´zary syndrome
(Abrams et al., 1991). Bouaziz et al. (2005) reported a similar
finding, showing that IL-2-treated NK cells isolated from
Se´zary syndrome patients are cytotoxic against Se´zary tumor
cells. As IL-21 did not induce apoptosis of malignant T cells,
these findings suggest that the antitumor activity of IL-21 is
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Figure 4. IL-21R mRNA levels in normal donors’ and patients’ PBMCs. The
expression of IL-21R mRNA was assessed by reverse transcription PCR using
PBMCs from three normal donors and six light tumor burden patients. Patient
cells showed an average (Avg) increase in IL-21R that approached, but did not
reach, statistical significance (Po0.07). Data represent means (þ SD) of
tested individuals.
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most likely mediated by an increase in NK and possibly
CD8þ T-cell cytolysis. This hypothesis is supported by a
number of animal studies showing that the antitumor effects
of IL-21 are primarily mediated by an increased cytotoxicity
of NK cells, CD8þ T cells, or both (Leonard and Spolski,
2005). Additional studies are underway to examine the
cytolytic response of patients’ CD8þ T cells and NK cells
against autologous tumor cell targets after treatment with
IL-21.
Although the overall percent target lysis is lower for Se´zary
syndrome patients’ cells compared to normal donors’ cells,
the magnitude of the increase in cytolytic activity after
treatment with IL-21 is much greater. This suggests that
patients’ NK-cell responses may be enhanced, and that the
diminished overall percent lysis is most likely owing to a
reduction in the number of circulating NK cells (Wysocka
et al., 2004), rather than a functional difference between
normal donor and patient NK cells.
One possible explanation for the enhanced cytolytic
activity of patients’ cells might be an increase in perforin
levels after incubation with IL-21. A number of animal studies
suggest that IL-21-induced antitumor activity is perforin-
dependent (Street et al., 2001; Ma et al., 2003), and an
increase in perforin would allow fewer cells to lyse a greater
number of targets. White et al. (2006) reported an analogous
finding for CD8þ T cells derived from HIVþ patients,
showing that culture of patients’ cells with IL-21 leads to a
greater degree of degranulation and higher perforin levels
than normal donors’ cells. Studies are underway to evaluate
perforin levels in both NK cells and CD8þ T cells derived
from Se´zary syndrome patients.
The enhanced cytolytic activity of patients’ cells after
incubation with IL-21 may also be explained by an
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Figure 5. Carboxyfluorescein diacetate succinimidyl ester proliferation
study results for normal donors’ CD4þ cells and patients’ CD4þ /CD26
T cells. PBMCs from three Se´zary patients and three normal donors were
treated with carboxyfluorescein diacetate succinimidyl ester, as described
previously, and cultured in medium alone, IL-21 (25 ng/ml), or plate-bound
anti-CD3 (0.5 mg/ml) in the presence of soluble anti-CD28 (0.5 mg/ml) for 4
days. Cells were then harvested, stained with the appropriate antibodies, and
analyzed for proliferation of all live lymphocytes (not shown), CD4þ
lymphocytes (shown for normal donors’ cells), and CD4þ /CD26
lymphocytes (shown for patients’ malignant T cells). (a) Data are shown for
cells from one representative patient and one representative normal donor.
(b) Data represent means (þ SD) of tested individuals and are presented as
average (Avg) precursor frequencies for patients’ and normal donors’ cells.
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Figure 6. Apoptosis study results for patients’ CD4þ /CD26 T cells.
PBMCs from five heavy tumor burden Se´zary patients were cultured in
medium alone, camptothecin (positive control), or with IL-21 (25 ng/ml). Cells
were then harvested at 48-, 72-, and 96-hour time points, stained with the
appropriate antibodies, and a TUNEL assay was performed. Cells were
analyzed by flow cytometry for the presence of apoptosis. Data shown are
averaged.
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upregulation of the IL-21R on these cells. A recent study by
Ueda et al. (2004) found that mRNA expression levels for the
IL-21R, but not IL-21, were significantly higher in cells
isolated from patients with adult T-cell leukemia than that in
normal donors. Our results suggest that there may be a similar
increase in IL-21R mRNA levels in Se´zary patients’ cells,
which could lead to an increased sensitivity to IL-21. These
observations are limited, however, as IL-21R was examined
on PBMCs rather than on distinct cell populations and data
approached, but did not reach, statistical significance.
Additional studies are underway to examine IL-21R levels
in discrete cell populations, including NK cells, CD8þ
T cells, and CD4þ T cells by reverse transcription PCR using
purified populations of cells and also by flow cytometry,
using anti-IL-21R.
It is also possible that Se´zary syndrome patients develop a
difference in NK-cell subpopulations, which may contribute
to the enhanced cytotoxic response of patients’ NK cells
following treatment with IL-21. Recent studies indicate
that there are two major populations of NK cells in
humans—CD56bright, which has a high capacity for IFNg
production and lower cytotoxicity, and CD56dim, which is
more cytotoxic but produces less IFNg (Lanier et al., 1986;
Fehniger et al., 1999; Cooper et al., 2001). Although
Se´zary syndrome patients have a reduced number of NK
cells overall, CD56dim cells may comprise a greater
proportion of NK cells in Se´zary syndrome patients, resulting
in an enhanced cytolytic response after exposure to IL-21
with only a modest increase in IFNg. We are currently
investigating the differences between the NK populations of
normal donors and Se´zary syndrome patients to test this
hypothesis.
Although IL-21-mediated NK-cell cytolytic activity is a
crucial component of the innate immune response to
malignant cells, several animal models have demonstrated
that antigen-specific IL-21-mediated CD8þ T-cell activity is
essential to attain a durable antitumor response (Ma et al.,
2003; Wang et al., 2003; Moroz et al., 2004). In this study,
IL-21 induces a modest but statistically significant increase
in CD69 expression on CD8þ T cells isolated from both Se´zary
syndrome patients and normal donors, but the magnitude of
this upregulation is greater for Se´zary syndrome patients. This
suggests that patients’ CD8þ T cells are not only functional,
but may also have an enhanced sensitivity to IL-21. This
enhanced responsiveness following IL-21 treatment may help
to explain why PBMCs isolated from Se´zary syndrome
patients but not normal donors have both a variable increase
in IFNg production and an increase in cytolytic activity
against SZ-4 target cells.
We determined that incubation with IL-21 alone did not
induce the proliferation of CD4þ /CD26 tumor cells.
Although IL-21 alone has not been shown to cause
proliferation of normal T cells (Parrish-Novak et al., 2000),
it has been found to enhance proliferation of T cells when
combined with other cytokines, including IL-2, IL-7, and
IL-15 (Parrish-Novak et al., 2000; Kasaian et al., 2002), and to
induce proliferation of malignant cells derived from patients
with adult T-cell leukemia (Ueda et al., 2004). It is therefore
essential to establish that IL-21, a potential therapeutic
antitumor cytokine in the treatment of Se´zary syndrome,
does not induce growth of malignant Se´zary cells.
Overall, these results suggest that IL-21 is a potent
stimulator of both innate and adaptive cell-mediated immune
responses, which could lead to immediate and lasting
antitumor effects. The ability to activate and amplify the
effects of CD8þ T cells and NK cells with IL-21 has
important therapeutic implications in the treatment of Se´zary
syndrome, as these cytotoxic cells likely play an essential role
in the control of disease progression. Furthermore, prelimi-
nary results from a recent phase I clinical trial using IL-21 for
the treatment of renal cell carcinoma demonstrate clinical
regressions of this solid tumor, which has been a notoriously
poor responder to single cytokine manipulation (Curti, 2006).
These results are especially encouraging for Se´zary syndrome
patients, as these patients are generally highly responsive to
immune manipulation, thus making the probability of
response to IL-21 treatment substantial. Although further
studies are needed to understand the toxic and therapeutic
effects of IL-21 in vivo in humans, these results have
important clinical implications, as they suggest that IL-21
could be a powerful new biologic agent in the treatment of
Se´zary syndrome patients.
MATERIALS AND METHODS
Patients
Se´zary syndrome patients were diagnosed on the basis of clinical,
histopathological, and immunohistological criteria. Patients’ circu-
lating malignant T cells were analyzed on 1 mm sections of formalin-
fixed peripheral blood buffy coats by the detection of mononuclear
cells with cerebriform nuclear morphology (Murphy, 1988). Se´zary
syndrome patients were divided into two groups based on tumor
burden. Patients with 10–30% circulating Se´zary cells were labeled
light tumor burden and those with greater than 30% circulating
Se´zary cells were labeled heavy tumor burden. All patients with
Se´zary syndrome underwent extracorporeal photopheresis approxi-
mately every 4 weeks (Rook et al., 1999a, b). None of the patients
studied had been treated with chemotherapy, radiation, or other
immunosuppressive drugs. As controls, blood samples from age-
matched healthy donors were used. Donation of blood by patients
and healthy donors conformed to the University of Pennsylvania
Institutional Review Board-Approved protocols. The Declaration of
Helsinki Principles was followed, and patients gave their written,
informed consent.
Reagents
IL-21 was provided as a gift by Zymogenetics (Seattle, WA). Anti-
CD3 and anti-CD28 antibodies were purchased from R&D systems
(Minneapolis, MN).
Preparation of PBMCs
PBMCs from Se´zary patients or normal donors were collected as
described previously (Rook et al., 1995). Cells were either suspended
immediately in culture media (RPMI 1640; Life Technologies,
Gaithersburg, MD) supplemented with 10% fetal bovine serum,
penicillin/streptomycin, and L-glutamine (all reagents purchased
from Gibco-BRL, Grand Island, NY) or in a 5% DMSO, 95% fetal
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calf serum freezing solution. Cells in freezing solution were stored at
1401C until thawing.
Carboxyfluorescein diacetate succinimidyl ester proliferation
assay and flow cytometric analysis
T-cell proliferation was tested using PBMCs that were pelleted and
resuspended in phosphate-buffered saline at a final concentration of
1 107 cells/ml and labeled in 0.5. mM (final concentration) of
carboxyfluorescein diacetate succinimidyl ester (Invitrogen, Carls-
bad, CA) for 10minutes at room temperature with gentle shaking.
Cells were washed with phosphate-buffered saline (Gibco-BRL),
resuspended in culture media, and stimulated with IL-21 (25 ng/ml)
or with anti-CD28 (0.5 mg/ml) on an anti-CD3-coated plate for 4
days. Cells were then harvested and stained with anti-CD26-PE
(phycoerythrin) and anti-CD4-APC (allophycocyanin). To evaluate
the expression of CD69 on NK cells or T cells, PBMCs were cultured
in media with IL-21 (25 ng/ml) for 36 hours and stained with
anti-CD3-PerCp (peridinin chlorophyll protein), anti-CD56-APC,
anti-CD16-APC, anti-CD69-FITC or anti-CD4-APC, anti-CD8-peri-
dinin chlorophyll protein, and anti-CD69-FITC. All antibodies were
purchased from BD Biosciences (San Jose, CA). Murine immunoglo-
bulins of appropriate isotypes were used as a control. Cells were
analyzed with the FACS Calibur (Becton Dickinson, San Jose, CA)
flow cytometer using CellQuest (Becton Dickinson) and Modfit
(Verity Software House, Topsham, ME). A total of 30,000 events
were collected to analyze all cell types.
Detection of cytokines
Viably frozen human PBMCs were thawed on the day of use and
cultured at 371C in 96-well plates at a density of 2 106 cells/ml per
well and incubated in media alone or in IL-21 (25 ng/ml). Culture
supernatants were harvested after 72 hours and tested for the
presence of IFNg by ELISA, according to the manufacturer’s
recommendations, using antibody pairs from R&D Systems (sensi-
tivity 5 pg/ml).
NK cytotoxicity assay
Viably frozen human PBMCs were thawed on the day of use and
resuspended in media, as described previously. Cells were cultured
at 371C in 96-well plates at a density of 4 106 cells/ml per well and
incubated in media alone or in IL-21 (25 ng/ml) for 36 hours. Cells
were then washed with phosphate-buffered saline (Gibco-BRL) and
plated at different concentrations. K562 human erythroleukemia
cells or SZ-4 cells, a Se´zary cell line derived from a proven Se´zary
syndrome tumor clone (Abrams et al., 1991), were used as targets.
A standard 4-hour Cr51-release assay was performed as described
previously (Rook et al., 1995).
Apoptosis assay
Viably frozen human PBMCs were thawed on the day of use and
resuspended in media, as described previously. Cells were cultured
at 371C in 24-well plates at a density of 2 106 cells/ml per well and
cultured for 48, 72, and 96 hours in media alone, IL-21 (25 ng/ml), or
camptothecin (Sigma-Aldrich Corp., St Louis, MO) as a positive
control for induction of apoptosis. A TUNEL assay was performed, as
described previously (Sgonc et al., 1994). Cells were then harvested
and labeled with Cy5-dUTP (Amersham Pharmacia Biotech,
Piscataway, NJ), anti-CD26-PE, and anti-CD4-APC and analyzed by
flow cytometry.
Real-time reverse transcription PCR
Viably frozen human PBMCs were thawed on the day of use for RNA
extraction using RNA STAT-60 (Tel-test, Inc., Friends Wood, TX).
Single-stranded cDNA was then synthesized using the high-capacity
cDNA archive kit (Applied Biosystems, Norwalk, CT), and the
expression levels of IL-21R mRNA and the internal reference b-actin
rRNA were measured using quantitative real-time reverse transcrip-
tion PCR using primers and reagents from Applied Biosystems,
according to the manufacturer’s instructions. Results were collected
and analyzed using an ABI PRISM 7500 HT sequence detector
(Applied Biosystems). Standard curves for both IL-21R and b-actin
were generated using cDNA derived from normal donors’ PBMCs
suspended in media, as described previously, and activated for
16 hours with plate-bound anti-CD3 and soluble anti-CD28 (Parrish-
Novak et al., 2002). All standards and samples were analyzed in
triplicate, and the average value was used for calculations.
Statistical analysis
Data are expressed as means7SD of tested individuals. Statistical
significance was determined using the Kruskal–Wallis test if
applicable.
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